PRTC Puretech Health
- 29.250
- 0.0000.00%
Puretech Health News
PureTech to Present at the Jefferies Global Healthcare Conference
PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. Difficile Infection
VE303 is an orally administered, potential first-in-class live biotherapeutic product candidate being developed to prevent recurrence of Clostridioides difficile infection (CDI) PureTech Health plc (NASDAQ:PRTC, LSE:
PureTech Health Sets $100 Mln Capital Return To Shareholders
PureTech Health Announces Launch of $100M Tender Offer At Premium Price of 250 Pence Per Share
The Company is offering to purchase up to 33,500,000 Ordinary Shares (including Ordinary Shares represented by ADSs) representing approximately 12 percent of the Company's issued ordinary share capita
PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announces the opening of its proposed $100 million tender offer (the "Tender Offer").
PureTech Founded Entity Seaport Therapeutics Presents Data From Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, a biopharmaceutical company that is charting a proven path in neuropsychiatry, today announced two poster presentations detailing the results from multiple clinical trials of SPT-300 at the Society of Biological Psychiatry Annual Meeting in Austin, TX. SPT-300 has been shown to retain the activity and potency of natural allopregnanolone in an oral form and has the potential to capture the breadth of the naturally occurring neurosteroid, which is believed to have significant therapeutic potential in a range of mood and anxiety disorders, including anxious depression.
PureTech Health: Share Capital and Pipeline Update
PureTech Health Plc (NASDAQ:PRTC) Q4 2023 Earnings Call Transcript
Earnings Call Summary | Puretech Health(PRTC.US) Q4 2023 Earnings Conference
The following is a summary of the PureTech Health Plc (PRTC) Q4 2023 Earnings Call Transcript:Financial Performance:PureTech Health ended 2023 with cash, cash equivalents and short-term investments of
PureTech Health Plc (PRTC) Q4 2023 Earnings Call Transcript
PureTech Health plc (PRTC) Q4 2023 Earnings Call Transcript
PureTech Health FY 2023 GAAP EPS $(0.24) Beats $(0.93) Estimate, Sales $3.330M Down From $15.618M YoY
PureTech Health (NASDAQ:PRTC) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.93) by 74.19 percent. The company reported $3.330 million in sales this q
Press Release: PureTech Announces Annual Results -44-
On May 9, 2022, the Group announced the commencement of a $50,000 share repurchase program (the "Program") of its ordinary shares of one pence each. In February 2024, the Group completed the Program a
PureTech Announces Annual Results for Year Ended December 31, 2023
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") today announces its results for the year ended December 31, 2023, as well as its cash balance as of the first quarter ended March 31, 2024.
PureTech Health (PRTC.US): The 2023 FY financial report achieved revenue of $3.33 million, previous value of $15.618 million; earnings per share were -0.24 US dollars, previous value of -0.18 US dollars.
PureTech Health (PRTC.US): The 2023 FY financial report achieved revenue of $3.33 million, previous value of $15.618 million; earnings per share were -0.24 US dollars, previous value of -0.18 US dollars.
PureTech Health Reports Strong 2023 Financial Position
Earnings Flash (PRTC.L) PURETECH HEALTH Posts FY24 Loss $-0.24
02:13 AM EDT, 04/25/2024 (MT Newswires) -- Earnings Flash (PRTC.L) PURETECH HEALTH Posts FY24 Loss $-0.24
PureTech Health Schedules Annual Financial Results Release
PureTech Completes Enrollment In Phase 2b ELEVATE IPF Trial Of LYT-100 (Deupirfenidone) In Idiopathic Pulmonary Fibrosis; Topline Results Expected In Q4 Of 2024
PureTech Completes Enrollment In Phase 2b ELEVATE IPF Trial Of LYT-100 (Deupirfenidone) In Idiopathic Pulmonary Fibrosis; Topline Results Expected In Q4 Of 2024
PureTech's LYT-200 Secures Receives FDA Fast Track Designation For Head And Neck Cancers
PureTech's LYT-200 Secures Receives FDA Fast Track Designation For Head And Neck Cancers
PureTech Health's Seaport Therapeutics Raises $100 Million at Launch
PureTech Health's (PRTC.L) 61.5%-owned unit Seaport Therapeutics raised $100 million in an oversubscribed series A financing round. The biotherapeutics group unit's series A financing round was co-led
Analysis
Price Target
No Data
